All In Biotech

Drug Trial Radar · NCT04580394

Crossover Trial of AD109 in Obstructive Sleep Apnea

Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea

Last checked: Nov 19, 2026Latest source record: Jan 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Oct 27, 2020

Primary completion

May 28, 2021

Study completion May 28, 2021

Sponsor

Lead sponsor
ApnimedIndustry
Sponsor type
Industry
First posted
Oct 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of AD109 versus its individual components or placebo in patients with obstructive sleep apnea.

Conditions

  • Obstructive Sleep Apnea

Interventions

  • AD109Drug

    Oral administration before bed

  • AtomoxetineDrug

    Oral administration before bed

  • R-oxybutyninDrug

    Oral administration before bed

  • PlaceboDrug

    Oral administration before bed

  • Digit System Substitution TestDiagnostic test

    a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hypoxic Burden (HB) Log10HB[(%*Min)/Hour]Time frame: 1 night (treatment duration) (0-8 hours collected continuously)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • Empire Clinical Research

    Pomona, California

  • Yale University

    New Haven, Connecticut

  • Teradan Clinical Trials

    Brandon, Florida

  • Clinical Trials of Florida

    Miami, Florida

  • The Neurological Center of North Georgia

    Gainesville, Georgia

  • CTI Clinical Research Center

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.